| __timestamp | BeiGene, Ltd. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6930000 | 504755000 |
| Thursday, January 1, 2015 | 7311000 | 838526000 |
| Friday, January 1, 2016 | 20097000 | 1177697000 |
| Sunday, January 1, 2017 | 62602000 | 1320433000 |
| Monday, January 1, 2018 | 195385000 | 1556200000 |
| Tuesday, January 1, 2019 | 388249000 | 1834800000 |
| Wednesday, January 1, 2020 | 600176000 | 1346000000 |
| Friday, January 1, 2021 | 990123000 | 1824900000 |
| Saturday, January 1, 2022 | 1277852000 | 2115900000 |
| Sunday, January 1, 2023 | 1504501000 | 2631300000 |
| Monday, January 1, 2024 | 2954400000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing operational expenses is crucial for sustained growth. Over the past decade, Regeneron Pharmaceuticals, Inc. and BeiGene, Ltd. have showcased contrasting strategies in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Regeneron consistently maintained higher SG&A expenses, peaking at approximately $2.63 billion in 2023, reflecting a 420% increase from 2014. In contrast, BeiGene's SG&A expenses surged by an astounding 21,600% over the same period, reaching $1.50 billion in 2023. This dramatic rise highlights BeiGene's aggressive expansion strategy. While Regeneron's expenses grew steadily, BeiGene's rapid increase suggests a focus on scaling operations and market penetration. As these companies continue to evolve, their SG&A efficiency will be pivotal in determining their competitive edge in the biotech industry.
Selling, General, and Administrative Costs: Johnson & Johnson vs Regeneron Pharmaceuticals, Inc.
Comparing SG&A Expenses: Pfizer Inc. vs BeiGene, Ltd. Trends and Insights
Breaking Down SG&A Expenses: Sanofi vs Regeneron Pharmaceuticals, Inc.
Comparing SG&A Expenses: Bristol-Myers Squibb Company vs Regeneron Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Bristol-Myers Squibb Company or BeiGene, Ltd.
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Insmed Incorporated
Cost Management Insights: SG&A Expenses for Regeneron Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.
Regeneron Pharmaceuticals, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Rhythm Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Veracyte, Inc.
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Supernus Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Ligand Pharmaceuticals Incorporated